Market Overview

Piper Jaffray Says Quidel Shares Can Continue To Rise On The Back Of New Deal With Alere

Share:
Piper Jaffray Says Quidel Shares Can Continue To Rise On The Back Of New Deal With Alere
Related QDEL
The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage
The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More
Related ALR
Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley
Wall Street's M&A Chatter From Sept. 26-Oct. 1: Nordstrom, US Concrete, Ecolab And More

Analysts at Piper Jaffray turned bullish on Quidel Corporation (NASDAQ: QDEL), mostly due to the company's "sweetening" of its already attractive Alere Inc (NYSE: ALR) asset acquisition. The firm's William R. Quirk upgrades Quidel's stock rating from Neutral to Overweight with a price target boosted from $35 to $50.

Quidel, a diagnostics maker, announced in July it would buy Alere's triage assets but on Monday announced it has revised the agreement to now include the full worldwide BNP business, Quirk highlighted. While the revised deal implies an additional $48 million in BNP revenue, more importantly, the deal will add $50 million to $60 million in EBITDA. In fact, the entire deal could now boost Quidel's annual EBITDA by around $100 million.

The analyst's 2018 earnings per share estimate were also moved higher by 64 percent to $1.34 per share and then rise another 41 percent in fiscal 2019.

"Whether it is luck or being at the right place at the right time, we believe Quidel has done it again and sweetened its already attractive Alere deal," the analyst emphasized.

Looking forward, Quidel's stock is expected to move higher as investors begin to digest the revised deal and accretion estimates, the analyst added. As such, a new multiple of 4x 2018 EV/pro forma revenue is appropriate as opposed to a prior 3x multiple which derives the analyst's new $50 price target.

At last check, shares of Quidel were up 8.12 percent at $44.23.

Related Links:

Mid-Morning Market Update: Markets Edge Higher; AutoZone Earnings Top Expectations

Benzinga's Top Upgrades, Downgrades For September 19, 2017

Latest Ratings for QDEL

DateFirmActionFromTo
Sep 2018Canaccord GenuityMaintainsBuyBuy
Aug 2018Canaccord GenuityMaintainsBuyBuy
Aug 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for QDEL
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Health Care Price Target Asset Sales Best of Benzinga

 

Related Articles (QDEL + ALR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Veritone Higher For Fourth Day In A Row

A Peek Into The Future For Mirati Therapeutics